An observational study in Esophageal Neoplasm and Esophageal Disease, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University Hospital, Lille · Observational
Background
Secondary objectives :
Methodology : European French-speaking retrospective multicentric study Inclusion criteria: All consecutive patients operated on, for a histologically proven carcinoma of the esophagus, the oesophago-gastric junction (Siewert type I and II), in surgical investigator centers between January 2000 and December 2010 Exclusion criteria: Siewert III type carcinoma of the oesophago-gastric junction , non surgical treatment of esophageal carcinoma Planned study period: The data will be collected over a 11-year period from January 2000 to December 2010. Follow up will be ascertained in May 2013.
Patients with an esophageal or junctional carcinoma (including SIewert type I and II) with surgical resection of the primary tumor inclusion date will be date of surgery all patients will be followed during 5 years after surgery or time of death
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's enrollment of 2,944 is above the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients operated on for a cancer of the esophagus , a Siewert I or II cancer of the oesophago-gastric junction
Exclusion Criteria:
Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
Procedure: Esophagectomy
Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
To identify predictors of recurrence after esophageal cancer surgery
clinical factors linked to 5-year recurrence will be identify through univariable and multivariable analysis
Time frame: 30 May 2012
5 year recurrence free survival
events: death and recurrence at 5 years after surgery
Time frame: 30 May 2012
5 year overall survival
all causes for death at 5 years after surgery
Time frame: 30 may 2012
Predictors of postoperative mortality and morbidity after surgery
30-day postoperative mortality and 30-day overall postoperative morbidity
Time frame: 30 May 2012
Impact of pCR on recurrence and survival
pathological complete response within the tumor and nodes
Time frame: 30 May 2012
Impact of neoadjuvant treatments on recurrence and survival
looking at the impact of neoadjuvant chemo and/or chemoradiation on oncological outcomes
Time frame: 30 May 2012
Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes
looking at the impact of nutritional support, endoscopic and surgical procedures on outcomes
Time frame: 30 May 2012
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille